Signaling by moderate kinase activity BRAF mutants

Stable Identifier
R-HSA-6802946
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
Summation

In addition to the highly prevalent and activating V600E BRAF mutations, numerous moderately activating and less common mutations have also been identified in human cancers (Forbes et al, 2015). Unlike the case for their highly activating counterparts, signaling through these mutant versions of BRAF depends both upon RAS binding and RAF dimerization (Wan et al, 2004; Freeman et al, 2013; Roring et al, 2012; reviewed in Lito et al, 2013; Lavoie and Therrien, 2015)

Literature References
PubMed ID Title Journal Year
22510884 Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

Röring, M, Herr, R, Fiala, GJ, Heilmann, K, Braun, S, Eisenhardt, AE, Halbach, S, Capper, D, von Deimling, A, Schamel, WW, Saunders, DN, Brummer, T

EMBO J. 2012
25907612 Regulation of RAF protein kinases in ERK signalling

Lavoie, H, Therrien, M

Nat. Rev. Mol. Cell Biol. 2015
23352452 Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling

Freeman, AK, Ritt, DA, Morrison, DK

Mol. Cell 2013
24202393 Tumor adaptation and resistance to RAF inhibitors

Lito, P, Rosen, N, Solit, DB

Nat. Med. 2013
25355519 COSMIC: exploring the world's knowledge of somatic mutations in human cancer

Forbes, SA, Beare, D, Gunasekaran, P, Leung, K, Bindal, N, Boutselakis, H, Ding, M, Bamford, S, Cole, C, Ward, S, Kok, CY, Jia, M, De, T, Teague, JW, Stratton, MR, McDermott, U, Campbell, PJ

Nucleic Acids Res. 2015
15035987 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Wan, PT, Garnett, MJ, Roe, SM, Lee, S, Niculescu-Duvaz, D, Good, VM, Jones, CM, Marshall, CJ, Springer, CJ, Barford, D, Marais, R

Cell 2004
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed